Session UENPS 1st International Congress of UENPS Abstract UENPS.1 Neonatal seizures Cristina Resende⁎, Nelson Neves, Nádia Brito, Adelaide Taborda Maternidade Bissaya barreto, Coimbra, Portugal Background and aim Neonatal seizures in term newborn are a neurological emergency and can be the identification of a dysfunction or important lesion of central nervous system, associated with subsequent neurodevelopment deficits. There are relative common with a variable clinic presentation and had with major risk the neonatal asphyxia. Materials and methods Retrospective study of individual patient records admitted with neonatal seizures and with gestation age more than 37 weeks during the period of January 1998 to December 2007). We analyse the demography factors, pregnancy and birth history, type of seizures, diagnose approaches and treatment. Results The prevalence was 1.9‰ (45 newborns). The delivery was disthocic in 68%. Have clonic seizures 53, 5%, and tonic 24%. More than half of the seizures occurred during the first 24 h life. Were treat with Phenobarbital 57%. The hypoxic ischemic encephalopathy was the most frequent aetiology occurred in 22%, cerebral stroke 9%, sepsis 9% and metabolic disease 9%. The mortality was 7%. We follow 38 of 42 survivors (medium 17, 5 months): no alteration – 68%; cerebra palsy – 10%; epilepsy – 8% e retarded development associated with cerebral palsy and epilepsy – 5%. Conclusions The prevalence of seizures in our unit was similar to the literature. Had diagnose 38% of cases, near 1/4 no need any medication and 1/3 had severe morbidity. doi:10.1016/j.earlhumdev.2008.09.017 Abstract UENPS.2 A multicenter, randomized trial on prophylactic bovine lactoferrin in preterm neonates for prevention of late-onset sepsis Paolo Manzoni a , Stolfi Ilaria⁎ ,b , Hubert Messner c , Rosario Magaldi d , Silvia Cattani e , Maria Betta f , Lina Bollani g , Lorenza Pugni h , Nicola Laforgia i , Luigi Memo j , Federica Vagnarelli k , Fabio Mosca h , Roberto Pedicino b , Livia Renzullo c , Matteo Rinaldi d , Fabrizio Ferrari e , Mario Giuseppe Romeo f , Mauro Stronati g , Michele Quercia i , Onofrio Sergio Saia j , Magnani Cristiana k , Gallo Elena a , Daniele Farina a a Neonatology, S.Anna Hospital, Torino, Italy b NICU, Policlinico Umberto I^, Roma, Italy c Neonatologia e TIN, Ospedale Regionale, Bolzano, Italy d UTIN Ospedali Riuniti, Foggia, Italy e Neonatologia e TIN, Università di Modena, Modena, Italy f U.O. TIN, Azienda Ospedaliera Universitaria Policlinico, Catania, Italy g Neonatologia, IRCCS Policlinico S. Matteo, Pavia, Italy h V.O TIN — Patologia Neonatale, Clinica Mangiagalli, Milano, Italy i NICU, Policlinico University Hospital, Bari, Italy j NICU, Ca' Foncello Hospital, Treviso, Italy k NICU, Arcispedale S.M.Nuova, Reggio Emilia, Italy Background and aim Lactoferrin (LF) is a mammalian milk glycoprotein that plays a major role in innate immune host defenses, with a wide array of biological (including anti-infective) properties. In animal models, its activity has been found to be emphasized by the combination with Lactobacillus Rhamno- susGG (LGG). We performed a multicenter, double-blind, placebo-controlled RCT to assess effectiveness and safety of prophylactic LF supplementation (alone or in combination with LGG) to preterm neonates in NICU for prevention of late-onset sepsis (LOS). Materials and methods During 8 months, all preterm VLBW neonates from 11 Italian NICUs were randomized to receive since birth either Bovine LF alone (100 mg/day, gr.A1; n =111) or in combination with LGG (6×109 CFU/day, A2; n =118), or placebo (B, n = 125) till the 30th day of life (45th for those < 1000 g at birth). Drugs and placebo were administered orally, once a day. Systematic surveillance for detection of sepsis and adverse effects was performed. LOS was defined as episodes occurring >5 days after birth, and microbiologically confirmed by isolation of a pathogen (any type) from blood, urine, peritoneal and cerebrospinal fluid. Results A total of 354 neonates were analysed. Their clinical, demographical and management characteristics did not differ, particularly related to the type of feeding and to the amounts of maternal milk intakes. Overall, LOS incidence was significantly lower in groups A1 and A2 (10.7% and 9.8% respectively) than in B (26.7%) (R.R. 0.32; 95% C.I. 0.16–0.68; p = 0.02 in A1; R.R 0.29; 95% C.I. 0.15–0.59; p = 0.001 in A2). The decrease in LOS incidence was similar both for episodes caused by Gram-positive, Gram-negative and fungal organisms. When comparing the two combined treatment groups vs. placebo, LOS decreased to 10.3% (R.R. 0.18; 95% C.I. 0.21–0.56; p < 0.001), No adverse effects or intolerances occurred. 0378-3782/$ – see front matter pii:S0378-3782(08)00173-4 Early Human Development 84 (2008) S7–S157 Contents lists available at ScienceDirect Early Human Development journal homepage: www.elsevier.com/locate/earlhumdev